NCT00111670已完成2 期
A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 291
- 主要终点
- Absolute change from baseline in HbAlc\n\n
研究概览
简要总结
This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor compared to placebo in patients with type 2 diabetes. The anticipated time on study treatment is < 3 months and the target sample size is 100-500 individuals.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •adult patients 18-75 years of age;
- •type 2 diabetes diagnosed >=1 month before screening;
- •no previous treatment, or previous treatment with no more than 2 oral medications.
排除标准
- •type 1 diabetes;
- •type 2 diabetes treated with insulin or a PPAR gamma agonist during the 3 months before screening;
- •patients who are pregnant, breastfeeding or not using a reliable contraceptive method.
研究组 & 干预措施
1
Experimental
干预措施: DPP-IV Inhibitor (Drug)
2
Experimental
干预措施: DPP-IV Inhibitor (Drug)
3
Experimental
干预措施: DPP-IV Inhibitor (Drug)
4
Experimental
干预措施: DPP-IV Inhibitor (Drug)
5
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Absolute change from baseline in HbAlc\n\n
时间窗: Week 12
次要结局
- Absolute change in FPG and absolute/relative change in insulin sensitivity, beta-cell-function, lipid profile, response rate(Week 12)
- AEs, vital signs, laboratory tests, body weight, waist/hip ratio, ECG\n(Throughout study)
研究者
相似试验
已完成
2 期
Cholinergic Urticaria - Efficacy of DupilumabCholinergic UrticariaNCT03749148Charite University, Berlin, Germany48
已完成
2 期
A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.Diabetes Mellitus Type 2NCT00460941Hoffmann-La Roche133
已完成
1 期
Single and Multiple Ascending Oral Dose Study of RX-10001 in Healthy VolunteersHealthyNCT00941018Resolvyx Pharmaceuticals, Inc56
已完成
3 期
Study of Divalproex Extended Release Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomania or Mild ManiaBipolar Spectrum Disorder With Moderate-to- Severe Hypomania or Mild ManiaNCT00278772Lindner Center of HOPE62
已完成
1 期
Safety and Tolerability of BVS857 in Subjects With Insulin ResistanceInsulin ResistanceNCT01435330Novartis Pharmaceuticals43